Skip to main content

Table 2 Comparison of clinical characteristics at baseline between healthy subjects and patients with ACO

From: Upregulated microRNA-125b-5p in patients with asthma-COPD overlap mediates oxidative stress and late apoptosis via targeting IL6R/TRIAP1 signaling

 

Healthy subjects (n = 22)

Patients with ACO (n = 27)

p-value

Age (years)

67.5 (9.5)

67.3 (11.4)

0.947

BMI (kg/m2)

25.0 (4.0)

23.1 (5.1)

0.152

Current smoker (%)

0 (0%)

8 (29.6%)

0.006

Pack/year

0

50.0 (30.0–75.0)

< 0.001

ACCI

4.0 (2.4)

4.7 (1.9)

0.230

mMRC score

N.A.

2.0 (1.0–3.0)

 

CAT score

N.A.

9.0 (6.0–15.0)

 

Hemogram parameters

 WBC count (1000/μL)

5.9 (2.4)

8.0 (2.5)

0.004

 Neutrophil (%)

59.9 (9.4)

56.4 (13.9)

0.324

 Lymphocyte (%)

31.2 (10.6)

32.0 (12.0)

0.806

 Monocyte (%)

6.5 (2.2)

6.4 (1.9)

0.928

 Eosinophil (%)

1.8 (0.8–2.9)

3.2 (1.9–5.1)

0.008

 AEC (/μL)

90.4 (48.6–158.2)

291.2 (121.8–432.0)

0.001

 NLR

1.9 (1.3–2.6)

1.9 (1.1–2.6)

0.469

 LMR

6.2 (3.5–7.5)

4.6 (3.7–6.9)

0.644

 Hemoglobin (g/dL)

13.7 (1.8)

14.2 (1.6)

0.271

 Albumin (g/dL)

4.2 (0.4)

4.4 (0.4)

0.247

Pulmonary function test

 Pre-BD FVC (%)

91.8 (10.9)

74.0 (16.8)

< 0.001

 Pre-BD FEV1 (%)

93.9 (10.9)

49.9 (17.3)

< 0.001

 Pre-BD FEV1/FVC

78.9 (75.8–84.1)

52.9 (45.1–60.3)

< 0.001

 Pre-BD FEF25%–75% (%)

82.0 (31.1)

20.2 (9.3)

< 0.001

 Post-BD FVC (%)

N.A.

77.4 (16.4)

 

 Post-BD FEV1 (%)

N.A.

54.7 (18.9)

 

 Post-BD FEV1/FVC

N.A.

53.7 (11.3)

 

 Post-BD FEF25%–75% (%)

N.A.

23.8 (11.9)

 

 BD response (%)

N.A.

2 (7.4%)a

 

Atopic diseases

 Asthma history

0 (0%)

14 (51.9%)

< 0.001

 Allergic rhinitis

0 (0%)

14 (51.9%)

< 0.001

 Atopic dermatitis

0 (0%)

3 (11.1%)

0.242

 AEs in the previous year

N.A.

2.0 (1.0–4.0)

 
  1. aBronchodilator response at enrollment, but 100% with documented bronchodilator response in other pulmonary function tests